



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> :  A61K 9/52, A61F 9/00 A61K 9/54, 9/10		A1	(11) International Publication Number: <b>WO 87/07833</b>  (43) International Publication Date: 30 December 1987 (30.12.87)
<p>(21) International Application Number: PCT/US87/01480</p> <p>(22) International Filing Date: 22 June 1987 (22.06.87)</p> <p>(31) Priority Application Number: 893,903</p> <p>(32) Priority Date: 20 June 1986 (20.06.86)</p> <p>(33) Priority Country: US</p> <p>(71) Applicant: SHACKNAI, Jonah [US/US]; 1747 Pennsylvania Avenue, N.W., Washington, DC 20006 (US).</p> <p>(72) Inventor: CARVAIS, Jean ; 657 Racquet Club Road, Fort Lauderdale, FL 33326 (US).</p> <p>(74) Agents: WEGNER, Harold, C. et al.; Wegner &amp; Bretschneider, P.O. Box 18218, Washington, DC 20036 (US).</p>		<p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent).</p> <p><b>Published</b>  <i>With international search report.  Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: ORAL SUSTAINED RELEASE MEDICAMENT</p> <p><b>(57) Abstract</b></p> <p>The dosage delivery system of the invention provides for the formulation in the saturated solution to be immediately available for absorption and for the medication in the microcapsule reservoirs to be released at a relatively constant quantity per hour. This ensures substantially linear therapeutic blood levels once state has been achieved. Since steady states are usually achieved within five half-lives, the invention will make the use of potentially toxic drugs (e.g., theophylline) safer and permit less frequent dosage application, thereby ensuring patient compliance.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	FR France	ML Mali
AU Australia	GA Gabon	MR Mauritania
BB Barbados	GB United Kingdom	MW Malawi
BE Belgium	HU Hungary	NL Netherlands
BG Bulgaria	IT Italy	NO Norway
BJ Benin	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic of Korea	SD Sudan
CF Central African Republic	KR Republic of Korea	SE Sweden
CG Congo	LI Liechtenstein	SN Senegal
CH Switzerland	LK Sri Lanka	SU Soviet Union
CM Cameroon	LU Luxembourg	TD Chad
DE Germany, Federal Republic of	MC Monaco	TG Togo
DK Denmark	MG Madagascar	US United States of America
FI Finland		

ORAL SUSTAINED RELEASE MEDICAMENTSUMMARY OF THE INVENTION

In a first aspect of the invention there is provided a dosage form for delivery of a fixed amount of a drug to provide a sustained release of said drug to a patient which comprises:

- (a) a graduated container for accepting a liquid oral sustained release medicament, said graduated container being calibrated in units to permit an accurate total dosage of said drug; and
- (b) a liquid oral sustained release medicament capable of providing even blood levels of a drug in the bloodstream of a patient over a prolonged period of time, which comprises a suspension comprising microcapsules of said drug suspended in a saturated solution of said drug, the saturated level of said drug being maintained over a prolonged period of time for sustained release to the bloodstream and at a substantially constant level by means of the dissolution of the microcapsules into solution to replace the drug that leaves said solution, thereby maintaining the saturated level of drug in solution.

In a preferred aspect said graduated container is a cylinder having plural markings on at least one edge to denote the total dosage for said drug when said cylinder is filled to a particular level with said liquid oral sustained release medicament.

In a further aspect said graduated container is a graduated eyedropper having plural markings on at least one edge to denote the total dosage for said drug when said graduated eyedropper is filled to a particular level with said liquid oral sustained release medicament.

In one embodiment of the invention, the sustained release medicament is insoluble or only slightly soluble in water and

said suspension includes a non-aqueous solvent. As an example of such a drug may be mentioned aspirin.

5 In another embodiment of the invention, said liquid oral sustained release medicament is soluble in water and said suspension is an aqueous suspension. Examples of drugs within this embodiment of the invention include theophylline and quinidine sulfate.

10 In accordance with a second embodiment of the invention there is provided a liquid oral sustained release medicament capable of providing even blood levels of a drug in the bloodstream of a patient over a prolonged period of time, which comprises a suspension comprising microcapsules of said drug suspended in a saturated solution of said drug, the saturated level of said drug being maintained over a prolonged 15 period of time for sustained release to the bloodstream and at a substantially constant level by means of the dissolution of the microcapsules into solution to replace the drug that leaves said solution, thereby maintaining the saturated level of drug in solution. This second aspect of the invention may be administered to a patient apart from the combination of the 20 first aspect of the invention, for example, by measuring the amount of the drug with a spoon.

The following examples illustrate the invention:

EXAMPLE I

25 There is prepared a sustained-release aqueous liquid suspension of theophylline. The water vehicle is saturated with theophylline and has microcapsules containing theophylline core material suspended in the water.

30 Since one gram of theophylline is soluble in approximately 120 ml of water, each 5 cc of saturated aqueous solution contains 41.67 mg of theophylline. By administering a suspension of microcapsules in a saturated aqueous vehicle it is possible to provide 200 mg of theophylline in 5 cc. This can be accomplished by incorporating into each 5 cc,

5 suspended microcapsules containing about 158.33 mg of theophylline and 41.67 mg of theophylline in solution. The quantity of theophylline in the microcapsules may be adjusted upward to compensate for the displacement of the saturated solution of theophylline.

10 A precise dosimeter can be included with the formulation package so that a precise dose may be administered, e.g., if the patient is to receive 200 mg every 12 hours, 5 ml is given or if the patient only required 100 mg every 12 hours, 2.5 ml may be given. This dosimeter may be a graduated cylinder or in the shape of an eyedropper, or other convenient form.

EXAMPLE II

15 Administration of the drug in accordance with Example I is illustrated as follows: An eight-year-old child who weighs 25 kilos (55 lb) should achieve a blood level of approximately 15 mcg/ml when given a theophylline dose of 24 mg/kg/day or 300 mg (7.5 ml of the above solution) every 12 hours. Since it is unlikely that any patient would be "average," serum concentrations should be monitored and the dose adjusted accordingly. A broad dosage flexibility is provided by the invention since 0.5 ml increments of suspension (20 mg of theophylline) can be measured with a high degree of accuracy in conventional liquid dosimeters.

EXAMPLE III

20 Another example of a pharmaceutical formulation that would be used in this invention is quinidine sulfate for the treatment of ventricular arrhythmias. One gram of quinidine sulfate is soluble in 500 ml of water or 20 mg quinidine sulfate is soluble in 10 ml water. Thus a suspension containing 500 mg of quinidine sulfate in 10 ml/water could be formulated by dissolving 20 mg of quinidine sulfate in aqueous solution and suspending in the solution 480 mg of microencapsulated quinidine sulfate.

A daily dose per kilogram of quinidine base can be estimated from this simple formula:

Daily Dose =  $(C)(CL)(1440)/F$  = average quinidine free base serum concentration (mg/ml) desired.

5 CL = total body drug clearance rate in ml/min/kg.

1440 = the number of minutes in a day.

F = the percentage bioavailability.

For example:

Daily Dosage =  $(.002 \text{ mg/ml})(4.5 \text{ ml/min/kg})(1440 \text{ min})$   
10 .99

Daily Dose =  $12.96$  = 13.1 mg/kg/day of free base  
.99

This corresponds to 15.8 mg/kg/day of quinidine sulfate (13.1 mg/kg/day). A woman weighing 63 kilos would require a daily dose of approximately 995 mg or approximately 10 ml every 12 hours. If needed, dosage can be adjusted in 25 mg (0.5 ml) increments.

20 The gradual release of medication from the microcapsules in the liquid suspension, after they enter the gastrointestinal tract, at a relatively constant quantity per hour, enables plasma levels of the medication to be maintained at relatively constant levels. It also permits patients to take medication at less frequent intervals, thereby promoting compliance with the prescribed dosage regimen. For example, 25 even though quinidine has a half-life of only 6.2 hours, it can be administered every 12 hours if incorporated into this system.

#### EXAMPLE IV

30 By following the same method of calculation as provided above for quinidine sulfate, a sustained release oral medication can be prepared for erythromycin, based upon the fact that 1 gm dissolves in 1000 ml of water.

#### EXAMPLE V

Utilization of the calculation techniques for quinidine sulfate, a sustained release oral medication can be prepared for Erythromycin ethylsuccinate, which is only slightly soluble in water but freely soluble in propylene glycol.

5

EXAMPLE VI

In place of the propylene glycol of Example V, there is substituted ethanol to make a saturated solution of Erythromycin ethylsuccinate.

10

EXAMPLE VII

By following the same method of calculation as provided above for quinidine sulfate, a sustained release oral medication can be prepared for Erythromycin estolate in propylene glycol.

15

EXAMPLE VIII

By following the same method of calculation as provided above for quinidine sulfate, a sustained release oral medication can be prepared for Erythromycin estolate in ethanol.

20

EXAMPLE IX

By following the same method of calculation as provided above for quinidine sulfate, a sustained release oral medication can be prepared for ampicillin, based upon the fact that 1 gram is soluble in 90 ml of water.

25

EXAMPLE X

By following the same method of calculation as provided above for quinidine sulfate, a sustained release oral medication can be prepared for Amoxicillin, as 1 gram is soluble in 370 ml of water.

30

EXAMPLE XI

Isosorbide dinitrate is only very slightly soluble in water, indicating an ethanolic medium. By following the same method of calculation as provided above for quinidine sulfate, a sustained release oral medication can be prepared for isosorbide dinitrate.

6

EXAMPLE XII

A propylene glycol suspension of isosorbide dinitrate is prepared as an alternate form for the sustained release form of Example XI.

5

EXAMPLE XIII

Tolbutamide is dissolved in an ethanolic medium. By following the same method of calculation as provided above for quinidine sulfate, a sustained release oral medication is prepared.

10

EXAMPLE XIV

A propylene glycol suspension of tolbutamide is prepared as an alternate form for the sustained release form of Example XIII.

15

EXAMPLE XV

By following the same method of calculation as provided above for quinidine sulfate, a sustained release oral medication can be prepared for prednisone, based upon the fact that 1 gm dissolves in 150 ml of water.

20

EXAMPLE XVI

A sustained release dosage form is made for the slightly water soluble hydrochlorothiazide.

25

EXAMPLE XVII

Probucol is practically insoluble in water, leading to the creation of an ethanol-based solvent system for a probucol dosage form.

EXAMPLE XVIII

A propylene glycol-based suspension is made for probucol replacing the ethanol.

30

EXAMPLE XIX

Atropine is soluble at the rate of one gram per 460 ml water. By following the same method of calculation as provided above for quinidine sulfate, a sustained release oral medication can be prepared.

WHAT IS CLAIMED IS:

1. A dosage form for delivery of a fixed amount of a drug to provide a sustained release of said drug to a patient which comprises:

5 (a) a graduated container for accepting a liquid oral sustained release medicament, said graduated container being calibrated in units to permit an accurate total dosage of said drug; and

10 (b) a liquid oral sustained release medicament capable of providing even blood levels of a drug in the bloodstream of a patient over a prolonged period of time, which comprises a suspension comprising microcapsules of said drug suspended in a saturated solution of said drug, the saturated level of said drug being maintained over a prolonged period of time for sustained release to the bloodstream and at a substantially constant level by means of the dissolution of the microcapsules into solution to replace the drug that leaves said solution, thereby maintaining the saturated level of drug in solution.

20 2. The dosage form of claim 1, wherein said graduated container is a cylinder having plural markings on at least one edge to denote the total dosage for said drug when said cylinder is filled to a particular level with said liquid oral sustained release medicament.

25 3. The dosage form of claim 1, wherein said graduated container is a graduated eyedropper having plural markings on at least one edge to denote the total dosage for said drug when said graduated eyedropper is filled to a particular level with said liquid oral sustained release medicament.

30 4. The dosage form of claim 1, wherein said liquid oral sustained release medicament is insoluble or only

slightly soluble in water and said suspension includes a non-aqueous solvent.

5. The dosage form of claim 1, wherein said liquid oral sustained release medicament is soluble in water and said suspension is an aqueous suspension.

6. The dosage form of claim 5, wherein said drug is theophylline.

7. The dosage form of claim 5, wherein said drug is quinidine sulfate.

10. The dosage form of claim 4, wherein said drug is aspirin.

15. 9. A liquid oral sustained release medicament capable of providing even blood levels of a drug in the bloodstream of a patient over a prolonged period of time, which comprises a suspension comprising microcapsules of said drug suspended in a saturated solution of said drug, the saturated level of said drug being maintained over a prolonged period of time for sustained release to the bloodstream and at a substantially constant level by means of the dissolution of the microcapsules into solution to replace the drug that leaves said solution, thereby maintaining the saturated level of drug in solution.

20. 10. The dosage form of claim 9, wherein said liquid oral sustained release medicament is insoluble or only slightly soluble in water and said suspension includes a non-aqueous solvent.

25. 11. The dosage form of claim 9, wherein said liquid oral sustained release medicament is soluble in water and said suspension is an aqueous suspension.

30. 12. The dosage form of claim 11, wherein said drug is theophylline.

13. The dosage form of claim 11, wherein said drug is quinidine sulfate.

9

14. The dosage form of claim 12, wherein said drug is aspirin.

5

10

15

20

25

30

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 87/01480

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC<sup>4</sup>: A 61 K 9/52; A 61 F 9/00; A 61 K 9/54; A 61 K 9/10

## II. FIELDS SEARCHED

Minimum Documentation Searched ?

Classification System	Classification Symbols
IPC <sup>4</sup>	A 61 K A 61 F

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched \*

## III. DOCUMENTS CONSIDERED TO BE RELEVANT\*

Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	FR, A, 882339 (M. GAZAURAN) 31 May 1943 see page 2, lines 39-47	1-3
Y	US, A, 4250166 (H. MAEKAWA) 10 February 1981 see column 1, lines 34-37; claims	1-3
	-----	

\* Special categories of cited documents: <sup>10</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the International filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

2nd November 1987

Date of Mailing of this International Search Report

1 DEC 1987

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

M. VAN MOL

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

---

INTERNATIONAL APPLICATION NO. PCT/US 87/01480 (SA 17749)

---

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 12/11/87

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

---

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A- 882339		None	
US-A- 4250166	10/02/81	None	

---